Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genetesis Inc.
Age
18–100
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. ≥ 18 years of age at the time of enrollment
2. Signs and symptoms of chest pain that prompted further evaluation by either a heart angiogram or a scan of the heart (coronary CT angiogram) within the previous 5 years
3. Willing to provide written informed consent
4. Non-obstructive CAD defined as 0 to 49% diameter reduction of a major epicardial vessel or a FFR\>0.80
5. Scheduled for CRT
6. No cardiac medications in the last 24 hours of an MCG-CF scan (with the exception of the patients enrolled in the data development set)
You may not be if
1. Patients unable to fit into device
2. Non-ambulatory patients
3. Patients who meet device contraindications
4. Patients unable to lie supine for 5 minutes
5. History of noncompliance (with medical therapy, protocol, or follow-up)
6. History of non-ischemic dilated or hypertrophic cardiomyopathy
7. Documented acute coronary syndrome (ACS) within previous 30 days
8. Left ventricular ejection fraction (LVEF) \<40%, New York Heart Association heart failure (NYHA HF) class III-IV, or hospitalization for Reduced ejection fraction (HFrEF) within 180 days
9. Stroke within previous 180 days or intracranial hemorrhage at any time
10. End-stage renal disease, on dialysis, or estimated glomerular filtration rate (eGFR) \<30 ml/min.
11. Severe valvular disease or likely to require surgery/Transcatheter aortic valve replacement (TVAR) within 3 years
12. Life expectancy \<3-yrs. due to non-cardiovascular comorbidity
13. Enrolled in a competing clinical trial
14. Prior intolerance to both an ACE-I and ARB
15. If intolerant to a statin unless taking a PCSK9 as a statin replacement by their clinical provider
16. Pregnancy
Clareo Health | MCG as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction
